| |
Comment |
 CYP inhbitors
|
 CYP1A2 [HSA:1544]
|
CYP2A6 [HSA:1548]
|
CYP2B6 [HSA:1555]
|
CYP2C8 [HSA:1558]
|
CYP2C9 [HSA:1559]
|
CYP2C19 [HSA:1557]
|
CYP2D6 [HSA:1565]
|
Abiraterone
|
Amiodarone [DG:DG00204]
|
Bepridil [DG:DG00333]
|
Bupropion
|
Strong (in vivo) |
Celecoxib
|
Weak (in vivo) |
Chlorphenamine [DG:DG01099]
|
Chlorpromazine [DG:DG00867]
|
Cidoxepin
|
Cimetidine [DG:DG00017]
|
Weak (in vivo) |
Cinacalcet
|
Moderate (in vivo) |
Clemastine [DG:DG00387]
|
Clobazam
|
Clomipramine [DG:DG00929]
|
Cobicistat
|
Cocaine [DG:DG00808]
|
Dacomitinib [DG:DG01793]
|
Desvenlafaxine [DG:DG00963]
|
Weak (in vivo) |
Dexchlorpheniramine [DG:DG01098]
|
Diltiazem [DG:DG00331]
|
Weak (in vivo) |
Diphenhydramine [DG:DG00390]
|
Doxepin [DG:DG00937]
|
Doxorubicin [DG:DG00696]
|
Duloxetine [DG:DG00962]
|
Moderate (in vivo) |
Echinacea
|
Weak (in vivo) |
Escitalopram [DG:DG00947]
|
Weak (in vivo) |
Fluoxetine [DG:DG00942]
|
Strong (in vivo) |
Febuxostat
|
Weak (in vivo) |
Gefitinib
|
Weak (in vivo) |
Halofantrine [DG:DG01021]
|
Hydralazine
|
Weak (in vivo) |
Hydroxychloroquine
|
Weak (in vivo) |
Hydroxyzine [DG:DG00912]
|
Imatinib [DG:DG00710]
|
Weak (in vivo) |
Labetalol [DG:DG00320]
|
Levomepromazine [DG:DG00868]
|
Levomethadone [DG:DG01002]
|
Lopinavir
|
Lorcaserin
|
Methadone [DG:DG00999]
|
Weak (in vivo) |
Metoclopramide [DG:DG00055]
|
Mibefradil [DG:DG00328]
|
Midodrine [DG:DG00224]
|
Mirabegron
|
Moclobemide
|
Paroxetine [DG:DG00944]
|
Strong (in vivo) |
Pazopanib
|
Perphenazine [DG:DG00875]
|
Propafenone [DG:DG00200]
|
Weak (in vivo) |
Quinidine [DG:DG00192]
|
Strong (in vivo) |
Ranitidine [DG:DG00018]
|
Weak (in vivo) |
 D00422 Ranitidine (USAN/INN)
D00673 Ranitidine hydrochloride (JP17/USP)
|
|
Ranitidine bismuth citrate
|
Ritonavir
|
Weak (in vivo) |
Sertraline [DG:DG00945]
|
Weak (in vivo) |
Stiripentol
|
Telithromycin
|
Weak (in vivo) |
Terbinafine [DG:DG00375]
|
Moderate (in vivo) |
Thioridazine [DG:DG00882]
|
Tripelennamine [DG:DG00383]
|
Vemurafenib
|
Weak (in vivo) |
Venlafaxine [DG:DG00959]
|
Verapamil [DG:DG00329]
|
Weak (in vivo) |
CYP3A4 [HSA:1576]
|
CYP3A5 [HSA:1577]
|
CYP3A7 [HSA:1551]
|
CYP3A [HSA:1576 1577 1551]
|
Almorexant
|
Alprazolam
|
Weak (in vivo) |
Amlodipine [DG:DG00322]
|
Weak (in vivo) |
Amiodarone [DG:DG00204]
|
Weak (in vivo) |
Amprenavir
|
Moderate (in vivo) |
Aprepitant [DG:DG00066]
|
Moderate (in vivo) |
Atazanavir [DG:DG00657]
|
Moderate (in vivo) |
Atorvastatin [DG:DG00355]
|
Weak (in vivo) |
Azithromycin [DG:DG00606]
|
Berberine [DG:DG01773]
|
Bicalutamide
|
Weak (in vivo) |
Boceprevir
|
Strong (in vivo) |
Casopitant
|
Ciclosporin
|
Weak (in vivo) |
Cilostazol
|
Weak (in vivo) |
Cimetidine [DG:DG00017]
|
Weak (in vivo) |
Ciprofloxacin [DG:DG00617]
|
Moderate (in vivo) |
Clarithromycin [DG:DG00605]
|
Strong (in vivo) |
Clotrimazole
|
Crizotinib
|
Conivaptan [DG:DG00276]
|
Strong (in vivo) |
Cobicistat
|
Chlorzoxazone
|
Dihydroergotamine
|
Diltiazem [DG:DG00331]
|
Moderate (in vivo) |
Dronedarone [DG:DG00207]
|
Ergotamine [DG:DG00834]
|
Erythromycin [DG:DG00436]
|
Moderate (in vivo) |
Everolimus
|
Fluconazole [DG:DG00371]
|
Moderate (in vivo) |
Fluoxetine [DG:DG00942]
|
Weak (in vivo) |
Fluvoxamine [DG:DG00946]
|
Weak (in vivo) |
Fosamprenavir [DG:DG00656]
|
Moderate (in vivo) |
Fosaprepitant
|
Gemfibrozil
|
Goldenseal
|
Weak (in vivo) |
Grapefruit juice
|
Strong (in vivo) |
Imatinib [DG:DG00710]
|
Moderate (in vivo) |
Indinavir
|
Strong (in vivo) |
Isoniazid [DG:DG00642]
|
Weak (in vivo) |
Istradefylline
|
Itraconazole
|
Strong (in vivo) |
Ivacaftor
|
Ketoconazole
|
Strong (in vivo) |
Lacidipine
|
Lapatinib [DG:DG00715]
|
Linagliptin
|
Lopinavir/ritonavir
|
Strong (in vivo) |
Lurasidone
|
Maraviroc
|
Mibefradil [DG:DG00328]
|
Strong (in vivo) |
Miconazole [DG:DG00004]
|
Nefazodone
|
Strong (in vivo) |
Nelfinavir [DG:DG00655]
|
Strong (in vivo) |
Nilotinib [DG:DG00716]
|
Weak (in vivo) |
Pazopanib
|
Posaconazole
|
Strong (in vivo) |
Propiverine [DG:DG00479]
|
Ranitidine [DG:DG00018]
|
D00422 Ranitidine (USAN/INN)
D00673 Ranitidine hydrochloride (JP17/USP)
|
|
Ranolazine [DG:DG00247]
|
Weak (in vivo) |
Ritonavir
|
Strong (in vivo) |
Roxithromycin
|
Saquinavir [DG:DG00653]
|
Strong (in vivo) |
Tacrolimus [DG:DG00439]
|
Telaprevir
|
Strong (in vivo) |
Telithromycin
|
Strong (in vivo) |
Ticagrelor
|
Troleandomycin
|
Tofisopam
|
Tolvaptan
|
Valsartan
|
Verapamil [DG:DG00329]
|
Moderate (in vivo) |
Voriconazole
|
Strong (in vivo) |
Zileuton
|
Weak (in vivo) |
CYP17 [HSA:1586]
|
|
|
CYP inducers
|
|
|
CYP substrates
|
|
|
Transporter inhibitors
|
ABCB1 [HSA:5243]
|
ABCB4 [HSA:5244]
|
ABCB11 [HSA:8647]
|
ABCC1 [HSA:4363]
|
ABCC2 [HSA:1244]
|
ABCC3 [HSA:8714]
|
ABCC4 [HSA:10257]
|
ABCG2 [HSA:9429]
|
SLC15A2 [HSA:6565]
|
SLCO1A2 [HSA:6579]
|
SLCO1B1 [HSA:10599]
|
SLCO1B3 [HSA:28234]
|
SLCO2B1 [HSA:11309]
|
SLC22A1 [HSA:6580]
|
SLC22A2 [HSA:6582]
|
Cetirizine [DG:DG01107]
|
Cimetidine [DG:DG00017]
|
FDA |
Diphenhydramine [DG:DG00390]
|
Famotidine
|
Pilsicainide [DG:DG01257]
|
Quinidine [DG:DG00192]
|
FDA |
Ranitidine [DG:DG00018]
|
D00422 Ranitidine (USAN/INN)
D00673 Ranitidine hydrochloride (JP17/USP)
|
|
Testosterone [DG:DG00460]
|
SLC22A3 [HSA:6581]
|
SLC22A8 [HSA:9376]
|
OAT1 [HSA:9356]
|
OAT2 [HSA:10864]
|
OAT3 [HSA:9376]
|
URAT1 [HSA:116085]
|
MATE1 [HSA:55244]
|
MATE2 [HSA:146802]
|
|
|
Transporter inducers
|
|
|
Transporter substrates
|
ABCB1 [HSA:5243]
|
ABCB4 [HSA:5244]
|
ABCB11 [HSA:8647]
|
ABCC2 [HSA:1244]
|
ABCC3 [HSA:8714]
|
ABCC4 [HSA:10257]
|
ABCG2 [HSA:9429]
|
OAT1 [HSA:9356]
|
OAT2 [HSA:10864]
|
OAT3 [HSA:9376]
|
SLC15A1 [HSA:6564]
|
SCL15A2 [HSA:6565]
|
SLCO1A2 [HSA:6579]
|
SLCO1B1 [HSA:10599]
|
SLCO1B3 [HSA:28234]
|
SLCO2B1 [HSA:11309]
|
SLC22A1 [HSA:6580]
|
SLC22A2 [HSA:6582]
|
Amantadine [DG:DG00860]
|
FDA |
Amiloride [DG:DG00275]
|
FDA |
Cetirizine [DG:DG01107]
|
Cimetidine [DG:DG00017]
|
FDA |
Cisplatin
|
Creatinine
|
Dopamine [DG:DG00213]
|
FDA |
Famotidine
|
FDA |
Memantine [DG:DG00986]
|
FDA |
Metformin [DG:DG00113]
|
FDA |
Nafamostat
|
Oxaliplatin
|
Pindolol
|
Pramipexole [DG:DG00863]
|
Procainamide [DG:DG00193]
|
FDA |
Ranitidine [DG:DG00018]
|
FDA |
D00422 Ranitidine (USAN/INN)
D00673 Ranitidine hydrochloride (JP17/USP)
|
|
Varenicline [DG:DG00995]
|
FDA |
Ranitidine [DG:DG00018]
|
D00422 Ranitidine (USAN/INN)
D00673 Ranitidine hydrochloride (JP17/USP)
|
|
Quinine [DG:DG01019]
|
Varenicline [DG:DG00995]
|
SLC22A3 [HSA:6581]
|
SLC28A2 [HSA:9153]
|
SLC28A3 [HSA:64078]
|
SLC29A1 [HSA:2030]
|
SLC29A2 [HSA:3177]
|
MATE1 [HSA:55244]
|
MATE2 [HSA:146802]
|
Drug interactions with metabolizing enzymes and transporters